DEPO DepoMed Inc.

Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Depomed, Inc. (DEPO) and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired Depomed, Inc. (NASDAQ:DEPO) securities between February 26, 2015 and August 7, 2017 (the “Class Period”). Investors have until October 17, 2017 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

On August 7, 2017, after the market had closed, Depomed disclosed that the Company had received a request for information from the ranking minority member of the United States Senate Committee on Homeland Security and Governmental Affairs related to the promotion of opioids. Depomed also disclosed that the Company had received subpoenas related to opioid sales and marketing from the Office of the Attorney General of Maryland and the United States Department of Justice. Following this news, shares of Depomed fell $3.09 per share, or 33.42%, to close at $6.15 on August 8, 2017.

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Depomed engaged in questionable practices in connection with the sales and marketing of the Company’s opioid products; (ii) the foregoing conduct, when it became known, would likely subject the Company to heightened legal and regulatory scrutiny; and (iii) as a result, Depomed’s public statements were materially false and misleading at all relevant times.

If you purchased or otherwise acquired Depomed securities during the Class Period and suffered a loss or continue to hold shares purchased prior to the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning the Depomed, Inc. lawsuit, please go to http://www.bespc.com/DEPO. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com.

EN
11/09/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DepoMed Inc.

 PRESS RELEASE

Depomed Inc. Announces Corporate Name Change to Assertio Therapeutics,...

Depomed Inc. Announces Corporate Name Change to Assertio Therapeutics, Inc. Name Change Reflects Company’s Focus on Neurology, Orphan and Specialty Businesses LAKE FOREST, Ill., Aug. 15, 2018 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT), a leading specialty pharmaceutical company committed to advancing patient care, has announced that its corporate name change from “Depomed, Inc.” to “Assertio Therapeutics, Inc.” became effective at 11:59 p.m. ET yesterday, August 14, 2018. In connection with the name change, the Company’s common stock will begin trading under a new ti...

 PRESS RELEASE

Depomed Announces Second-Quarter 2018 Financial Results

Depomed Announces Second-Quarter 2018 Financial Results -- Raises Full-Year Earnings and Adjusted EBITDA Guidance Range and Lowers Full-Year Net Sales Guidance Range for the Neurology Franchise -- -- Confirms Regulatory Plan to File for FDA Approval of Cosyntropin Depot by Year End -- -- Announces Agreement with PDL BioPharma to Monetize Royalty Stream; Company Received $20 Million in Cash -- -- Announces Planned Change in Company Name from Depomed to Assertio Therapeutics;Remains On-Track to Transition to New Corporate Headquarters in Lake Forest, Illinois -- LAKE FOREST, Ill., Aug. 0...

 PRESS RELEASE

Depomed to Report Second-Quarter 2018 Financial Results on Wednesday, ...

Depomed to Report Second-Quarter 2018 Financial Results on Wednesday, August 8, 2018 LAKE FOREST, Ill., July 09, 2018 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release second-quarter 2018 financial results on Wednesday, August 8, 2018, before the open of markets. Following the announcement, the Company will host a conference call beginning at 8:30 a.m. ET to discuss its results. Participants can access the live webcast from the Investor Relations section of Depomed's website at . Please access the website 15 minutes prior to the start of the call to dow...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch